Clinical trials: Injectables
HIV Infections
The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir
Although CAB LA PrEP has been proven efficacious in blinded randomized controlled clinical trials, additional research is needed to evaluate effectiveness in real world settings as well as to identify effective implementation…
- Trial name
- ImPrepCab (NCT05515770)
- Testing
- Cabotegravir Injection
- Where
- Brazil
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Evandro Chagas National Institute of Infectious Disease
Non-small Cell Lung Cancer
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of BIND-014 in patients with advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT01792479
- Testing
- BIND-014
- Where
- 17 sites in United States, Russia
- Volunteers
- 64 people
- Sponsor
- BIND Therapeutics
Schizophrenia
A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.
The purpose of this study is to evaluate the efficacy of paliperidone palmitate compared with placebo in the prevention of recurrence of the symptoms of schizophrenia and to assess the safety and tolerability of paliperidone…
- Trial name
- NCT00111189
- Testing
- Paliperidone Palmitate
- Where
- 55 sites in United States, Costa Rica and 7 more
- Volunteers
- 414 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
HIV Infections
Satisfaction of HIV-infected Patients Treated With Cabotegravir-rilpivirine Injectable Dual Therapy
Question arises as to whether this new treatment "Cabotegravir-rilpivirineactually" improves patient satisfaction and whether it is well suited to everyone, especially those with a history of irregular follow-up.
- Trial name
- CABORI (NCT05697289)
- Testing
- satisfaction survey
- Volunteers
- 150 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Schizophrenia
A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia
The purpose of this study is to evaluate the effectiveness and safety of risperidone, formulated as a long-acting injectable drug, compared with risperidone tablets in the treatment of patients with schizophrenia.
- Trial name
- NCT00240708
- Testing
- risperidone
- Volunteers
- 205 people
- Sponsor
- Janssen Pharmaceutical K.K.
Midface Volume Deficit
Safety and Effectiveness of Mosaic for the Treatment of Midface Volume Deficit
The goal of this clinical trial is to study whether the Mosaic Injectable Dermal Implant is a safe and effective treatment for age-related midface volume deficit in adults who are at least 22 years of age.
- Trial name
- PRIME (NCT07710443)
- Testing
- Injectable dermal implant
- Where
- 5 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Helios Aesthetics Inc.
Head and Neck Cancer
Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells.
- Trial name
- NCT00022217
- Testing
- carboplatin, cisplatin-e therapeutic implant, paclitaxel
- Where
- 4 sites in United States
- Sponsor
- Matrix Pharmaceutical
Advanced, Metastatic Breast Cancer
A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of Letrozole SIE (injectable) compared to Femara® (oral tablet), both given together with ribociclib, for the first-line treatment of postmenopausal women with…
- Trial name
- SIE-3 (NCT07340658)
- Volunteers
- 300 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Bipolar Disorders, Schizophrenia
Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI)
The primary aim of this study is to determine the feasibility of long-acting injectable naltrexone administration in a clinical trial in patients with SMI who also have a diagnosis of alcohol dependence.
- Conditions
- Bipolar Disorders, Schizophrenia, Schizoaffective Disorders, Alcohol Dependence
- Trial name
- vivitrol (NCT00453804)
- Testing
- injectable naltrexone, oral naltrexone
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- State University of New York - Upstate Medical University
HIV (Human Immunodeficiency Virus)
Project SPEED - Streamlined Protocol for Early Engagement and Delivery of HIV Prevention With Long-acting Injectable Cabotegravir: A Nurse-driven Protocol
Project SPEED (Streamlined Protocol for Early Engagement and Delivery of HIV Prevention) is a pragmatic, cluster randomized implementation study evaluating a nurse-driven model for delivering long-acting injectable cabotegravir…
- Trial name
- Project SPEED (NCT07346508)
- Testing
- nurse-driven protocol for delivering Long-acting Injectable Cabotegravir (LAI-CAB) for HIV pre-exposure prophylaxis (PrEP)
- Volunteers
- 250 people
- Sponsor
- KC Care Health Center
Urothelial Carcinoma, Cholangiocarcinoma
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
BIND-014 (docetaxel nanoparticles for injectable suspension) is being studied in patients with advanced urothelial carcinoma, cervical cancer, cholangiocarcinoma or carcinomas of the biliary tree and squamous cell carcinoma of…
- Conditions
- Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- iNSITE2 (NCT02479178)
- Testing
- BIND-014 (docetaxel nanoparticles for injectable suspension)
- Where
- 23 sites in United States, Russia
- Volunteers
- 73 people
- Sponsor
- BIND Therapeutics
Psychotic Disorders
Family Perspectives:Treatment of Psychiatric Illnesses With Atypical Long Acting Injectable Antipsychotic Medication
Patients who have schizophrenia, schizoaffective disorder, a psychotic disorder, and are being treated with a medication called Risperidone Long Acting Injectable medication or another antipsychotic medication are candidates for…
- Trial name
- NCT00287027
- Testing
- Risperdal Long Acting Injectable Antipsychotic Medication
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Alliance on Mental Illness New Hampshire
Relapsing Forms of Multiple Sclerosis
Plegridy Observational Program
The primary objectives of the study are to determine the incidence of serious adverse events (SAEs) in participants with relapsing forms of multiple sclerosis (MS) in routine clinical practice and to assess the overall long-term…
- Trial name
- POP (NCT02230969)
- Testing
- peginterferon beta-1a
- Where
- 152 sites in United States, Australia and 12 more
- Volunteers
- 1,208 people
- Sponsor
- Biogen
Schizophrenia
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
A study to evaluate the safety, tolerability, and PK of an injectable form of KarXT in participants with schizophrenia
- Trial name
- NCT07061288
- Testing
- KarXT
- Where
- 8 sites in United States
- Volunteers
- 131 people
- Sponsor
- Bristol-Myers Squibb
Uveitis
Imaging of Uveitis Patients Receiving Injectable Fluocinolone Acetonide Implant
We will prospectively observe patients with uveitis who are either active or were recently active in the previous 6 months and are treated with the i-FA implant.
- Trial name
- PANTHER (NCT04340505)
- Testing
- Fluocinolone Acetonide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Cardiovascular Disease
Safety and Feasibility of the Injectable BL-1040 Implant
This is a Phase I, multi-center, open label study designed to assess the safety and feasibility of the injectable BL-1040 implant to provide scaffolding to infarcted myocardial tissue.
- Trial name
- NCT00557531
- Testing
- BL-1040
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- BioLineRx, Ltd.
Class II Furcation Defect
Treatment of Class II Mandibular Furcation Defects
The aim of this study is to investigate the clinical efficiency and radiographic outcomes following minimally invasive surgical technique with xenograft and i-PRF versus i-PRF in the management of class II furcation defects in…
- Trial name
- NCT07876973
- Testing
- Injectable-PRF (I-PRF), sticky bone (I-PRF+Xenograft)
- Where
- Egypt
- Volunteers
- 24 people
- Sponsor
- Cairo University
Visceral Leishmaniasis
Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis
Symptomatic Visceral Leishmaniasis(VL)is fatal; Due to the increasing resistance to standard therapy with antimonials, there is a need for new safe, efficacious, low-cost therapies for the treatment of VL.
- Trial name
- NCT00216346
- Testing
- Paromomycin sulfate, Amphotericin B
- Where
- 4 sites in India
- Volunteers
- 667 people
- Sponsor
- PATH
Facial Wrinkles
A Study to Compare Subject Comfort During and After Injections With the Study Products and the Safety of the Non-FDA Approved Product for the Correction of Nasolabial Folds (NLFs)
The purpose of this research study is to compare subject comfort during and after injection with NADGL and Captique® Injectable Gel, in the nasolabial folds.
- Trial name
- NCT00417469
- Testing
- NADGL
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Genzyme, a Sanofi Company
Mid-facial Volume Deficit Related to Aging
Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmentation
Multicenter, single-blind, randomized, "no-treatment" control study to demonstrate the safety and effectiveness of VOLUMA XC for deep injection for cheek augmentation to correct age-related volume deficit in the mid-face.
- Trial name
- NCT00978042
- Testing
- Juvéderm® VOLUMA XC
- Where
- 2 sites in United States, Canada
- Volunteers
- 345 people, healthy volunteers welcome
- Sponsor
- Allergan